Pharmaceuticals & Biotech Canadian Community
Our community narratives are driven by numbers and valuation.
Pharmaceuticals & Biotech Canadian Investing Ideas
Waiting for the Inevitable
Catalysts Federal rescheduling of marijuana from Schedule I to Schedule III of the Controlled Substances Act is an inevitability from a scientific and sociopolitical perspective within five years. Rescheduling will eliminate the application of the punitive s.Read more
Cybin will achieve a solid 14.7% profit margin within 5 years
Cybin’s aggressive analyst price targets make sense when you view the company through a true late-stage biotech lens rather than a speculative psychedelic stock. With more than US$225 million in cash after retiring all debt, Cybin is now one of the only fully funded companies in the entire sector with enough runway to complete multiple Phase 3 trials and deliver two major clinical readouts—Phase 2 CYB004 data in Q1 2026 and pivotal Phase 3 CYB003 results in Q4 2026.Read more
New era of chemotherapy
BioNxt is developing two platform technologies: a sublingual thin-film technology (ODF) for smart drug delivery and a novel chemotherapy platform in which the active ingredient is activated directly in the tumor—targeting and killing cancer cells while sparing healthy cells. The ODF technology is protected by a European broad patent (intention-to-grant, May 2025), covering a wide range of sublingual active ingredients and is being nationalized in key markets.Read more
Pre-Market Explosion
Organigram Holdings Inc. has seen some significant developments in the past four months: ✓ Acquisition of Motif Labs: In December 2024, Organigram acquired Motif Labs, a Canadian cannabis company, for C$90 million upfront.Read more
Cybin Set to Revolutionize Psychedelic Therapy with CYB003's Promising Results
It sounds like Cybin (CYBN) is gaining serious traction in the psychedelic therapy space! Guggenheim’s $35 price target is pretty aggressive, considering the stock is currently trading at a fraction of that.Read more
Regulatory Uncertainty And Oversupply Will Hamper Progress Yet Spark Resilience
Key Takeaways Regulatory uncertainty and operational constraints may limit revenue growth and profitability despite the company's expansion and innovation in emerging and established markets. Intense competition, price compression, and commoditization threaten margins, long-term pricing power, and the financial benefits of future acquisitions.Read more
GrowCo Capacity And Global Markets Will Unlock Potential
Key Takeaways Expanded cultivation capacity and international market access are expected to drive revenue growth and increased market diversification. Strong brand performance and a shift to higher-margin products support improved profitability and margin expansion.Read more
Expanding Retail Channels And E-Commerce Will Boost Market Reach
Key Takeaways Expansion in North America's retail channels and e-commerce initiatives is positioned to drive sustainable revenue growth through enhanced reach and customer experience. Strategic partnerships, acquisitions, and focused R&D innovation are set to diversify the portfolio and accelerate market expansion, bolstering revenues and competitiveness.Read more
European Expansion And Operational Improvements Will Unlock Cannabis Potential
Key Takeaways Expanding internationally and innovating with premium and alternative products are expected to drive sustainable revenue growth and strengthen brand equity across key markets. Cost-cutting measures and operational improvements aim to enhance margins and position the company for success, particularly if U.S. federal legalization advances.Read more
